Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Abstract
PMID
Authors Alexander Drilon; Jia Yu; Zhiyong He; Yongsheng Wang; Kejing Tang; Tianqing Chu; Shutan Liao; Junjun Zhang; Xinlong Zheng; Jaime Rubio-Perez; Matteo Repetto; Brendan Putz; Shengxiang Ren
Title Abstract CT061: A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 86 8_Supplement April 17, 2026
URL https://aacrjournals.org/cancerres/article/86/8_Supplement/CT061/782915/Abstract-CT061-A-phase-I-study-of-the-type-II-ROS1
Abstract Text Background: ROS1 tyrosine kinase inhibitors (TKIs) are highly effective in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance remains a challenge, particularly solvent front (SF) mutations like G2032R and D2033N, and the central beta sheet (Cβ6) mutation L2086F. ANS03 is a next generation type II TKI targeting both ROS1 and TRK, possessing a broad spectrum of acquired drug-resistant mutation coverage. In preclinical studies, ANS03 was more potent than repotrectinib against SF mutations and more potent than repotrectinib or zidesamtinib against L2086F. Method: A phase 1 study (NCT06716138) was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS03 in participants with locally advanced or metastatic solid tumors harboring a ROS1 or NTRK alteration. Dose escalation was determined by Bayesian optimal interval design. Response was assessed by investigators using RECIST V1.1. Results: As of January 6, 2026, the dose escalation study is ongoing. Five dose levels (15mg qd, 30mg qd, 45mg qd, 67.5mg qd and 90mg qd) have been completed. A total of 20 NSCLC patients harboring ROS1/NTRK fusions were enrolled. No dose-limiting toxicities were observed. The most frequently reported treatment related adverse events (TRAE) were low grade, including the elevation of AST/ALT (80%), bilirubin (35%) and LDH (35%). Grade ≥3 TRAE occurred in 25% of patients. Only low grade neurotoxicities (15%) including dizziness, dysgeusia and pain in the limbs occurred. Among 18 efficacy evaluable ROS1 fusion-positive cancers, objective response rates (ORRs) were 38.8% (7/18) for all enrolled patients and 54.5% (6/11) for patients previously received ≥2L systemic therapy and at least 1 prior ROS1 TKI. Of the latter, six patients were pre-treated with 2-4 ROS1 TKIs including lorlatinib, repotrectinib, taletrectinib, and zidesamtinib. Among heavily pretreated patients, one patient posted 5 prior lines of systemic therapy (3 prior TKIs) with an L2086F mutant cancer had a confirmed partial response (PR) with ANS03 at 12 weeks. Two additional patients who received ≥6 prior lines of systemic therapy and ≥4 prior TKIs had a PR at the first tumor assessment and remain on ANS03 therapy. Conclusions: ANS03 had a manageable safety profile with a low incidence of neurotoxicity. In ROS1 fusion-positive NSCLCs, promising preliminary anti-tumor activity was achieved, including against ROS1 L2086F.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 fusion lung non-small cell carcinoma predicted - sensitive ANS03 Phase I Actionable In a Phase I trial, ANS03 treatment demonstrated manageable safety and preliminary efficacy in patients with non-small cell lung cancer harboring a ROS1 fusion, resulting in an objective response rate of 38.8% (7/18) in the overall cohort and 54.5% (6/11) in patients previously treated with at least 2 lines of previous systemic therapy including a prior ROS1 TKI (Cancer Res (2026) 86 (8_Supplement): CT061; NCT06716138). detail...